Pharmaceutical Industry Makes Steady Progress Toward Meeting 2023 DSCSA Interoperability Requirements
2020 Barcode Assessment Documents Year-Over-Year Improvements
News provided by
Share this article
Share this article
EWING, N.J., Feb. 8, 2021 /PRNewswire/ A new GS1 US Barcode Assessment study shows that the pharmaceutical industry is making continued, steady progress toward interoperability, with a growing majority of products now properly serialized according to 2013 Drug Supply Chain Security Act (DSCSA) requirements. Conducted in 2020 by AmerisourceBergen Corporation, McKesson Pharmaceutical and Cardinal Health, in collaboration with
GS1 US, the study found that over 90 percent of packages and cases scanned at these three companies met all of the labeling requirements, with three years remaining until the final DSCSA deadline in 2023.
• Cautions FG, Corporate Agencies Against Ordering Vaccine Without Approval
• Insists NAFDAC Must Give Go Ahead For Vaccine Usage In Nigeria, Despite WHO Approval
• Agency To Track, Trace, Monitor Vaccine Distribution With Technology
The National Agency for Food and Drug Administration and Control (NAFDAC) has warned the public to be wary of using the fake COVID-19 vaccines circulating in Nigeria, saying they can cause COVID-like illnesses and other serious diseases that could kill.
Director General of the agency, Prof. Mojisola Adeyeye, who raised the alarm, also warned government establishments and agencies, as well as private companies and big corporation, against ordering the vaccines without its approval, noting that COVID-19 vaccines are new and the side effects or adverse events must be well monitored; hence should not be used by the public.
•Global deaths surpass 2 million
Onyebuchi Ezigbo in Abuja
The National Agency for Food and Drug Administration and Control (NAFDAC) yesterday said it has reports of the importation of fake COVID-19 vaccines into Nigeria.
Addressing a virtual press conference, the Director General of the agency, Prof Mojisola Christianah Adeyeye pleaded with Nigerians to avoid the fake vaccines, saying, “they can cause Covid-like illnesses or other serious diseases that could kill.”
She said the agency had not received any application from Covid vaccine manufacturers yet and therefore no vaccines had been approved by NAFDAC.
“Covid-19 vaccines are new, and the side effects or adverse effects must be well monitored, therefore, if NAFDAC does not approve, the public should not use,” the NAFDAC boss said.
The National Agency for Food and Drug Administration and Control (NAFDAC) plans to use traceability with GS1 Technology to monitor COVID-19 vaccine distribution, using Global Trade Item Number (GTIN), the Director–General of NAFDAC, Prof. Mojisola Adeyeye, says.